Skip to content

Kestra Medical Technologies

US · KMTS #2924 by market cap Listed 2025
25.10 -1.53 -5.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 26.35 -1.05%
After-hours 25.10 0.00%
31.6318.8225.102026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on KMTS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -3.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 6.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Gross margin 51.4% Better than 65%
Operating margin -141.6% Better than 6%
Net margin -138.4% Better than 6%
Return on equity -56.6% Better than 8%
Return on invested capital -47.5% Better than 6%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -7.0% Better than 57%
6-month return 16.0% Better than 79%
12-month return (ex latest month) 8.5% Better than 44%
Distance below 52-week high 21.5% Better than 57%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.4x Better than 83%
Debt to assets 13.1% Better than 65%
Interest coverage -16.4x Better than 11%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 21.9% Better than 36%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.36%
1M -11.24%
3M -7.92%
6M +20.91%
YTD -5.35%
1Y +0.44%

Key statistics

Price & volume

Prev close
26.63
Open
26.14
Day range
24.94 - 27.50
Avg price
25.64
Volume
435.08K
Turnover
11.15M
Amplitude
9.59%
52-week range
17.34 - 31.99

Valuation

P/E
-10.33
P/E (TTM)
-9.92
P/B
6.72
EPS
-2.43
Net profit
-144.74M
Net assets
222.34M

Share structure

Market cap
1.50B
Float cap
773.66M
Shares out
59.56M
Float shares
30.82M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2025-03-06
52-week range 53% of range
17.34 31.99

21.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+7.48M net over the window

Short interest

Shares short
4.10M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Kestra Medical Technologies (KMTS)?

Kestra Medical Technologies last traded at 25.10. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Kestra Medical Technologies's market cap?

About 1.50B.

What is the P/E ratio of Kestra Medical Technologies?

The trailing twelve-month P/E is -9.92. The Valuation tab shows it against the stock's own five-year range.

Does Kestra Medical Technologies pay a dividend?

Kestra Medical Technologies does not currently pay a regular dividend.

Is Kestra Medical Technologies a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 30.60, which implies 21.9% upside from the current price. This is not investment advice.

What is Kestra Medical Technologies's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Kestra Medical Technologies a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Kestra Medical Technologies discussion 0 comments

Add a comment